Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

4,612

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

4,612 results for “Labels”

Learn how ShareScore rates datasets ↗
zenodo12/100

DELETE (incorrect upload) - Dataset for Doshi et al. "The Possible Harms of Statins: What do Product Labels, Patient Package Inserts, and Pharmacy Leaflets Tell Us?"

<p>This dataset inadvertently contained the wrong files.&nbsp; The correct files are available at https://doi.org/10.5281/zenodo.1464310</p>

restrictedJul 2018View details →
zenodo12/100

BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm

<p>The database is related to the article &ldquo;BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm&rdquo;. In this database we reported all the clinical and anamnestic data of the patients who completed the trial (e.g. 32 high-frequency episodic migraine subjects and 28 of them completed the trial).&nbsp; After a 28-day baseline period, subjects underwent 4 subsequent onabotulinum toxin-A treatments according to the phase III research evaluating migraine prophylaxis therapy (PREEMPT) paradigm, 12-weeks apart. Onabotulinum toxin-A reduced monthly migraine days by 3.68 days. Thirty-nine percent of the patients experienced a &ge;50% reduction in monthly migraine days. Onabotulinum toxin-A also reduced the number of headache days and the intake of acute medications. Disability and quality of life (QoL) scores improved markedly.</p>

restrictedApr 2022View details →
zenodo12/100

Is early MIDAS reduction at 3 months the best indicator predictor for erenumab treatment continuation? A open-label trial

<p>This database includes the raw data linked with the paper &ldquo;Is early MIDAS reduction at 3 months the best indicator predictor for erenumab treatment continuation? A open-label trial&rdquo;, published on The Journal of Headache and Pain.</p> <p>&nbsp;</p> <p>In this paper, we described migraine disability, quantified as a MIgraine Disability ASsessment (MIDAS).</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A moderate to severe disability, MIDAS score  11, is required for prescription.</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Score reduction of at least 50% after the first three months (T3) is mandatory to continue treatment.</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary aim of this study:</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - to evaluate whether 50% MIDAS reduction at T3 (MIDASRes) is a reliable response predictor of one-year erenumab treatment (classified as a reduction of baseline MMDs 50%).</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The 50% reduction of monthly migraine days (MMD) at T3 Co-primary outcome</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Secondary outcomes:</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - the search of other predictors represents</p> <p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methods:</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In this prospective, open-label study, 77 CM patients (mean age 49.8&plusmn;9.5 years, chronicity history 13.1&plusmn;10.3years, 93.5% of medication overuse headache) were treated with erenumab 70-140mg subcutaneous injections every 28 days for one year (T13). We assessed demographic and headache features, monthly migraine and headache days (MMD and MHDs respectively), days and doses of symptomatic intake. Patients also completed questionnaires evaluating migraine related disability (MIDAS and HIT-6), psychological comorbidities (HADS-A and HADS-D), quality of life (MSQ and 0 to 100 visual analogue scale) and allodynia (ASC-12). ANOVA for repeated measures was performed for quantifying erenumab efficacy and logistic regression model was used for evaluating one-year predictors of response.</p> <p>&nbsp; &nbsp; &nbsp; &nbsp;</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Results:</p> <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erenumab induced a sustained reduction of MMDs, MHDs and symptomatic intake during treatment. At T13 64.9% of patients presented MMDs baseline reduction 50% (RespondersT13). At T3, 55.8% of patients were MIDASRes. Contextually, 55.4% of patients were MMD Responders, these were also more likely to qualify as RespondersT13 when compared to non-responders (83.3% vs 42.9%; p=0.001). MMD response at T3 also demonstrated to be a predictor of long-term outcome according to a multivariate analysis ((Exp(B)=7.128; p=0.001)). When MIDAS reduction at T3 is considered as decision-making predictor of long-term outcome, 36.0% of patients who may benefit from 1-year erenumab administration are early excluded. By contrast, a lower percentage of Responders T13 (16%) would be discontinued if MIDASRes or MMD responders at T3 were alternatively considered.</p>

restrictedJun 2022View details →
zenodo12/100

xMP: A Cross-lingual Multi-label Media Profiling Dataset

<p>We propose xMP, a zero-shot cross-linguistic assessment benchmark for factual and political bias in media coverage. We gathered data to create a multilingual test set of media profiling tasks in 34 languages and 18 language families. This allowed us to evaluate model performance and expand work based on English resources to other languages.</p>

restrictedAug 2023View details →
geo12/100

Methylation pseudotime analysis for label-free profiling of the temporal chromatin landscape with long-read and single-molecule resolution [ATAC-seq]

GEO Series GSE290974. Homo sapiens. 16 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenMar 2025View details →
geo12/100

Chem-seq data from 5'-biotin-DRB-labelled human U2OS cells

GEO Series GSE106193. Homo sapiens. 2 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenOct 2022View details →
geo12/100

Bioluminescence-activated proximity labeling for spatial multi-omics

GEO Series GSE276085. Mus musculus; Homo sapiens. 27 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMay 2025View details →
nasa12/100

VL1/VL2 MARS LABELED RELEASE V1.0

The Labeled Release (LR) instrument on each Viking Lander operated throughout the Primary Mission and continued into the Extended Mission. The basic analysis cycle for the Labeled Release experiment was to deliver a sample of martian soil to one of four test cells, seal the cell and moisten the soil with an aqueous solution of carbon-14 labeled organic media. A second nutrient injection was typically done about 7-8 Mars days after the first injection. The test cell was continuously monitored for the release of radioactive labeled gas as an indicator of heterotrophic metabolism. Viking Lander 1 (VL1) conducted four analysis cycles with two nutrient injections for cycles 1, 2, and 4 and three injections for cycle 3. Viking Lander 2 (VL2) conducted five analysis cycles. The first four cycles had two nutrient injections each, and the fifth cycle had one injection [LEVIN&STRAAT1976B

restrictednotspecifiedMar 2025View details →
zenodo8/100

The intracranial tumor segmentation challenge: ICTS 2021-image labels

<p>This dataset was retrieved from clinical work of radiosurgery. It contains brain tumor labels of 150 patients.</p>

restrictedOct 2021View details →
zenodo4/100

20231127_Labelled metabolomes_Part2

Open the record for dataset details and reuse information.

restrictedDec 2023View details →
zenodo4/100

labeled images

<p>labeled images</p>

restrictedAug 2023View details →
zenodo4/100

satellite label data

<p>Label data</p>

restrictedSep 2023View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.